Top

Published in:

01-04-2014 | Original Research

Aspirin Use is Associated with Lower Prostate Cancer Risk in Male Carriers of BRCA Mutations

Authors: Matthew Cossack, Cameron Ghaffary, Patrice Watson, Carrie Snyder, Henry Lynch

Published in: Journal of Genetic Counseling | Issue 2/2014

Abstract

Previous studies have shown that male BRCA mutation carriers stand at increased risk of developing prostate cancer and have concerns about developing cancer. Genetic counseling practitioners often discuss strategies for reducing the risk of cancer for patients at high risk due to their genetic background. Addressing modifiable health habits is one such strategy. Unfortunately, modifiable risk factors for prostate cancer have only been documented in the general population and have not yet been studied in the BRCA carrier subpopulation. Therefore, this study aimed to identify modifiable risk factors for prostate cancer in BRCA carriers. We examined prostate cancer risk factors in 74 men who were part of families with a BRCA mutation. This study examined nine dichotomous variables including: exercise, history of vasectomy, smoking history, alcohol use, finasteride use, statin use, aspirin use, coffee use, and vitamin use. The survey was sent to all cases of prostate cancer in the Hereditary Cancer Center Database at Creighton University with a known BRCA status. This study confirmed the protective benefits of daily aspirin use, which have been observed in previous studies of the general population, and suggests its benefit in BRCA carriers. Protective benefits from regular vigorous exercise and daily coffee use trended towards significance, but neither factor withstood the Bonferroni Correction for multiple comparisons.

Burn, J., Gerdes, A. M., Macrae, F., Mecklin, J. P., Moeslein, G., Olschwang, S., & Bishop, D. T. (2011). Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. The Lancet, 378(9809), 2081–2087.CrossRef

Burn, J., Mathers, J., & Bishop, D. T. (2013). Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC). Recent Results in Cancer Research, 191, 157–183.PubMedCrossRef

Carter, B. S., Beaty, T. H., Steinberg, G. D., Childs, B., & Walsh, P. C. (1992). Mendelian inheritance of familial prostate cancer. Proc. Natl. Acad. Sci. USA, 89, 3367–3371.PubMedCentralPubMedCrossRef

Cuzick, J., Otto, F., & Baron, J. A. (2009). Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. The Lancet Oncology, 10, 501–507.PubMedCrossRef

De Nunzio, C., Kramer, G., Marberger, M., Montironi, R., Nelson, W., Schroder, F., & Tubaro, A. (2011). The controversial relationship between benign prostatic hyperplasia and prostate cancer: The role of inflammation. European Urology, 60, 106–117.PubMedCrossRef

Edwards, S. M., & Eeles, R. A. (2004). Unravelling the genetics of prostate cancer. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics, 129C, 65–73.PubMedCrossRef

Edwards, S. M., Kote-Jarai, Z., Meitz, J., Hamoudi, R., Hope, Q., Osin, P., & Eeles, R. A. (2003). Two Percent of Men with Early-Onset Prostate Cancer Harbor Germline Mutations in the BRCA2 Gene. The American Journal of Human Genetics, 72(1), 1–12.CrossRef

Friedenreich, C. M., McGregor, S. E., Courneya, K. S., Angyalfi, S. J., & Elliott, F. G. (2004). Case–control study of lifetime total physical activity and prostate cancer risk. American Journal of Epidemiology, 159(8), 740–749.PubMedCrossRef

Hickey, K., Do, K. A., & Green, A. (2001). Smoking and prostate cancer. Epidemiologic Reviews, 23(1), 115–125.PubMedCrossRef

Honda, G. D., Bernstein, L., Ross, R. K., Greenland, S., Gerkins, V., & Henderson, B. E. (1988). Vasectomy, cigarette-smoking, and age at 1st sexual intercourse as risk-factors for prostate-cancer in middle-aged men. British Journal of Cancer, 57, 326–331.PubMedCentralPubMedCrossRef

Kote-Jarai, K., Leongamornlet, D., Saunders, E., Tymrakiewicz, M., Castro, E., Mahmud, N., et al. (2011). BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. British Journal of Cancer, 105(8), 1230–1234.PubMedCentralPubMedCrossRef

Leongamornlert, D., Mahmud, N., Tymrakiewicz, M., Saunders, E., Dadaev, T., Castro, E., & Kote-Jarai, Z. (2012). Germline BRCA1 mutations increase prostate cancer risk. British Journal of Cancer, 106(10), 1697–1701.PubMedCentralPubMedCrossRef

McLaughlin, J. K., Mandel, J. S., Mehl, E. S., & Blot, W. J. (1990). Comparison of next-of-kin with self-respondents regarding questions on cigarette, coffee, and alcohol consumption. Epidemiology, 1(5), 408–412.PubMedCrossRef

O’Neill, G. P., & Ford-Hutchinson, A. W. (1993). Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Letters, 330, 157–160.CrossRef

Ostrand-Rosenberg, S., & Sinha, P. (2009). Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer. The Journal of Immunology, 182(8), 4499–4506.PubMedCentralPubMedCrossRef

Pienta, K. J., & Esper, P. S. (1993). Risk-factors for prostate cancer. Annals of Internal Medicine, 118, 793–803.PubMedCrossRef

Platz, E. A., Leitzmann, M. F., Fisvanathan, K., Rimm, E. B., Stampfer, M. J., Willett, W. C., & Giovannucci, E. (2006). Statin drugs and risk of advanced prostate cancer. Journal of the National Cancer Institute, 98, 1819–1825.PubMedCrossRef

Shafique, K., McLoone, P., Qureshi, K., Leung, H., Hart, C., & Morrison, D. S. (2012). Coffee consumption and prostate cancer risk: Further evidence for inverse relationship. Nutrition Journal, 11, 42.PubMedCentralPubMedCrossRef

Shebl, F. M., Sakoda, L. C., Black, A., Koshiol, J., Andriole, G. L., Grubb, R., & Hsing, A. W. (2012). Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO Study. British Journal of Cancer, 107, 207–214.PubMedCentralPubMedCrossRef

Siegel, R., Naishadham, D., & Jemal, A. (2012). Cancer statistics, 2012. CA: a Cancer Journal for Clinicians, 62, 10–29.

Smith, W., DeWitt, D., & Garavito, R. (2000). Cyclooxygenases: Structural, cellular, and molecular biology. Annual Review of Biochemistry, 69, 145–182.PubMedCrossRef

Stock, D., Groome, P. A., & Siemens, D. R. (2008). Inflammation and prostate cancer: A future target for prevention and therapy? Urologic Clinics of North America, 35, 117–130.PubMedCrossRef

Strømsvik, N., Råheim, M., Oyen, N., Engebretsen, L. F., & Gjengedal, E. (2010). Stigmatization and male identity: Norwegian males’ experience after identification as BRCA1/2 mutation carriers. Journal of Genetic Counseling, 19, 360–370.PubMedCrossRef

Strømsvik, N., Råheim, M., & Gjengedal, E. (2011). Cancer worry among Norwegian male BRCA1/2 mutation carriers. Familial Cancer, 10, 597–603.PubMedCentralPubMedCrossRef

Thompson, D., & Easton, D. F. (2001). Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. American Journal of Human Genetics, 68, 410–419.PubMedCentralPubMedCrossRef

Thompson, D., & Easton, D. F. (2002). Cancer incidence in BRCA1 mutation carriers. Journal of the National Cancer Institute, 94, 1358–1365.PubMedCrossRef

Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., & Coltman, C. A. (2003). The influence of finasteride on the development of prostate cancer. The New England Journal of Medicine, 349, 215–224.PubMedCrossRef

Tymchuk, C. N., Barnard, R. J., Heber, D., & Aronson, W. J. (2001). Evidence of an inhibitory effect of diet and exercise on prostate cancer cell growth. The Journal of Urology, 166, 1185–1189.PubMedCrossRef

Wilson, K. M., Kasperzyk, J. L., Rider, J. R., Kenfield, S., van Dam, R. M., Stampfer, M. J., & Mucci, L. A. (2011). Coffee consumption and prostate cancer risk and progression in the health professionals follow-up study. Journal of the National Cancer Institute, 103, 876–884.PubMedCentralPubMedCrossRef

Title: Aspirin Use is Associated with Lower Prostate Cancer Risk in Male Carriers of BRCA Mutations
Authors: Matthew Cossack
Cameron Ghaffary
Patrice Watson
Carrie Snyder
Henry Lynch
Publication date: 01-04-2014
Publisher: Springer US
Published in: Journal of Genetic Counseling / Issue 2/2014
Print ISSN: 1059-7700
Electronic ISSN: 1573-3599
DOI: https://doi.org/10.1007/s10897-013-9629-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Aspirin Use is Associated with Lower Prostate Cancer Risk in Male Carriers of BRCA Mutations

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Acceptability of Telemedicine and Other Cancer Genetic Counseling Models of Service Delivery in Geographically Remote Settings

Predictive Genetic Testing in Children: Constitutional Mismatch Repair Deficiency Cancer Predisposing Syndrome

Specific Psychosocial Issues of Individuals Undergoing Genetic Counseling for Cancer – A Literature Review

Consumer Preferences for the Predictive Genetic Test for Alzheimer Disease

Disclosure Pattern and Follow-Up After the Molecular Diagnosis of BRCA/CHEK2 Mutations

Psychosocial Burden of Sickle Cell Disease on Parents with an Affected Child in Cameroon